Greater Intermountain Node Receives 7-Year NIH NIDA Renewal

Adam J. Gordon, MD, MPH, FACP, DFASAM, and Gerald (Jerry) Cochran, MSW, PhD, have been awarded a 7-year renewal for the Greater Intermountain Node (GIN) from the NIH National Institute on Drug Abuse (NIDA). This renewal solidifies GIN’s vital role in advancing research on substance use disorders and overdose prevention.

Founded in 2019, GIN is one of only 16 NIDA Clinical Trials Network (CTN) nodes nationwide. Over the past six years, it has been at the forefront of developing and testing innovative interventions for opioid use disorder (OUD), expanding research into diverse healthcare settings, and bringing cutting-edge expertise to Utah, the surrounding region, and the nation.

Over the next seven years, GIN will broaden its focus beyond OUD to address a wider spectrum of substance use disorders (SUDs) and overdose prevention. Drs. Gordon and Cochran will lead this evolution by leveraging their expertise in non-addiction care settings, supporting vulnerable communities, and influencing health service policies, with more information about their project available here. Their mission includes pioneering new research, expanding training initiatives, engaging with communities, and ensuring the dissemination of findings. To learn more about the Greater Intermountain Node and its groundbreaking work, visit their website.